eff Cancer Research Results
eff, efficacy: Click to Expand ⟱
| Source: |
| Type: |
Power to enhance an anti cancer effect
|
AML, Acute Myeloid Leukemia: Click to Expand ⟱
Scientific Papers found: Click to Expand⟱
eff↑, ROS↑, Apoptosis↑, eff↓,
AntiTum↑, GlucoseCon↓, ROS↑, TumCP↓, eff↓, Glycolysis↓,
eff↓, other↝, ROS↑, eff↓, eff↓,
ROS↑, MMP↓, cl‑Casp3↑, cl‑Casp9↑, cl‑PARP↑, eff↓,
TumCCA↑, Apoptosis↑, i-ROS↑, cycA1/CCNA1↓, CycB/CCNB1↓, P21↑, Cyt‑c↑, MMP↓, Bax:Bcl2↑, Casp9↑, Casp3↑, PARP↓, eff↓, *antiOx↑, *Inflam↓, *hepatoP↑, selectivity↑, NF-kB↓, *ROS↓,
SUV39H↓, Apoptosis↑, ROS↑, TumCCA↑, tumCV↓, Casp3↑, Casp9↑, Fas↑, FasL↑, DR4↑, P21↑, eff↓, eff↑,
TOP1↑, TOP2↑, eff↓,
| - |
in-vitro, |
lymphoma, |
U937 |
|
|
|
- |
in-vitro, |
AML, |
Jurkat |
|
|
|
TumCP↓, selectivity↑, Apoptosis↑, TumCCA↑, DNAdam↑, eff↓, ROS↑, tumCV↓,
ROS↑, GSH↓, eff↓, cl‑PARP↑, proCasp3↑, proCasp9↑, MMP↓, Cyt‑c↑, Diablo↑,
| - |
in-vivo, |
Nor, |
EL4 |
|
|
|
- |
in-vitro, |
AML, |
Jurkat |
|
|
|
JNK↑, Cyt‑c↑, FasL↑, BAX↑, ROS↑, *ROS↑, MKP1↓, MKP2↓, selectivity∅, tumCV↑, Cyt‑c↑, Casp3↑, GSH/GSSG↓, ROS↑, mt-ROS↑, *ROS↑, eff↓,
tumCV↓, Apoptosis↑, ROS↑, eff↓, DR4↑, DR5↑, TRAIL↑,
Casp8↑, Casp9↑, Casp3↑, ROS↑, ERK↑, cl‑PARP↑, MMP↓, eff↓,
Apoptosis↑, ROS↑, MMP↓, Casp3↑, Bcl-2↓, eff↓,
| - |
in-vitro, |
BC, |
MDA-MB-231 |
|
|
|
- |
in-vitro, |
BC, |
MDA-MB-468 |
|
|
|
- |
in-vitro, |
AML, |
HL-60 |
|
|
|
ROS↑, p62↓, eff↓,
Showing Research Papers: 1 to 14 of 14
* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 14
Pathway results for Effect on Cancer / Diseased Cells:
NA, unassigned(tgid=0) ⓘ
SUV39H↓, 1,
Redox & Oxidative Stress(tgid=1) ⓘ
GSH↓, 1, GSH/GSSG↓, 1, ROS↑, 13, i-ROS↑, 1, mt-ROS↑, 1,
Mitochondria & Bioenergetics(tgid=3) ⓘ
MMP↓, 5,
Core Metabolism/Glycolysis(tgid=4) ⓘ
GlucoseCon↓, 1, Glycolysis↓, 1,
Cell Death(tgid=5) ⓘ
Apoptosis↑, 6, BAX↑, 1, Bax:Bcl2↑, 1, Bcl-2↓, 1, Casp3↑, 5, cl‑Casp3↑, 1, proCasp3↑, 1, Casp8↑, 1, Casp9↑, 3, cl‑Casp9↑, 1, proCasp9↑, 1, Cyt‑c↑, 4, Diablo↑, 1, DR4↑, 2, DR5↑, 1, Fas↑, 1, FasL↑, 2, JNK↑, 1, MKP1↓, 1, MKP2↓, 1, TRAIL↑, 1,
Transcription & Epigenetics(tgid=7) ⓘ
other↝, 1, tumCV↓, 3, tumCV↑, 1,
Autophagy & Lysosomes(tgid=9) ⓘ
p62↓, 1,
DNA Damage & Repair(tgid=10) ⓘ
DNAdam↑, 1, PARP↓, 1, cl‑PARP↑, 3,
Cell Cycle & Senescence(tgid=11) ⓘ
cycA1/CCNA1↓, 1, CycB/CCNB1↓, 1, P21↑, 2, TumCCA↑, 3,
Proliferation, Differentiation & Cell State(tgid=12) ⓘ
ERK↑, 1, TOP1↑, 1, TOP2↑, 1,
Migration(tgid=13) ⓘ
TumCP↓, 2,
Immune & Inflammatory Signaling(tgid=16) ⓘ
NF-kB↓, 1,
Drug Metabolism & Resistance(tgid=21) ⓘ
eff↓, 16, eff↑, 2, selectivity↑, 2, selectivity∅, 1,
Functional Outcomes(tgid=23) ⓘ
AntiTum↑, 1,
Total Targets: 51
Pathway results for Effect on Normal Cells:
Redox & Oxidative Stress(tgid=1) ⓘ
antiOx↑, 1, ROS↓, 1, ROS↑, 2,
Immune & Inflammatory Signaling(tgid=16) ⓘ
Inflam↓, 1,
Functional Outcomes(tgid=23) ⓘ
hepatoP↑, 1,
Total Targets: 5
Scientific Paper Hit Count for: eff, efficacy
Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include :
-low or high Dose
-format for product, such as nano of lipid formations
-different cell line effects
-synergies with other products
-if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:2 Cells:% prod#:% Target#:961 State#:% Dir#:1
wNotes=0 sortOrder:rid,rpid
Home Page